Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

BACKGROUND: We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The objectives of the study were to determine the optimal dose for further use and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranki, Tuuli, Pesonen, Sari, Hemminki, Akseli, Partanen, Kaarina, Kairemo, Kalevi, Alanko, Tuomo, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kankainen, Matti, Backman, Charlotta, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Heiskanen, Raita, Jaderberg, Magnus, Juhila, Juuso, Priha, Petri, Suoranta, Laura, Vassilev, Lotta, Vuolanto, Antti, Joensuu, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791966/
https://www.ncbi.nlm.nih.gov/pubmed/26981247
http://dx.doi.org/10.1186/s40425-016-0121-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791966/
https://www.ncbi.nlm.nih.gov/pubmed/26981247
http://dx.doi.org/10.1186/s40425-016-0121-5

Ejemplares similares